ESR1 and breast cancer: Indeed, miR-222 is supposed to increase cell migration in the epithelial to mesenchymal transition acting downstream of the RAS-RAF-MEK oncogenic pathway [65, 67] and to be a promising therapeutic target for estrogen-receptor downregulated breast cancer [68].